AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26440415 — intervention group
Group type: EXPERIMENTAL
Intervention: NE-SM1 NEPLUS nebulizer (test nebulizer)
Number of subjects: 20
Study 26440415 — intervention group
Group type: COMPARATOR
Intervention: Pariboy SX nebulizer (control nebulizer)
Number of subjects: 20
Study 27128831 — intervention group
Group type: COMPARATOR
Intervention: Bazedoxifene 20 mg
Number of subjects: 107
Study 27128831 — intervention group
Group type: COMPARATOR
Intervention: Bazedoxifene 40 mg
Number of subjects: 107
Study 27128831 — intervention group
Group type: COMPARATOR
Intervention: Bazedoxifene 80 mg
Number of subjects: 107
Study 27128831 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene (5 mg and greater)
Number of subjects: 107
Study 27128831 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene (various doses)
Number of subjects: 107
Study 27128831 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene (1, 2.5, 5, 10, 20, 40, and 80 mg)
Number of subjects: 107
Study 27128831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 22427895 — intervention group
Group type: EXPERIMENTAL
Intervention: IV cannulation skills laboratory training (n=41)
Number of subjects: 81
Study 22427895 — intervention group
Group type: COMPARATOR
Intervention: Bedside teaching (n=40)
Number of subjects: 81
Study 20848369 — intervention group
Group type: EXPERIMENTAL
Intervention: Box and Block Test (BBT)
Number of subjects: 59
Study 20848369 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine-Hole Peg Test (NHPT)
Number of subjects: 59
Study 20848369 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Research Arm Test (ARAT)
Number of subjects: 59
Study 17686444 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed/platinum-based doublets (cisplatin or carboplatin)
Number of subjects: 0
Study 17686444 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (cisplatin plus etoposide)
Number of subjects: 0
Study 17686444 — intervention group
Group type: COMPARATOR
Intervention: 3- and 4-drug regimens
Number of subjects: 0
Study 17686444 — intervention group
Group type: COMPARATOR
Intervention: Non-platinum-based regimens
Number of subjects: 0
Study 15655129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 13677
Study 15655129 — intervention group
Group type: COMPARATOR
Intervention: B2B2 genotype
Number of subjects: 13677
Study 11985904 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE-guided cardioversion
Number of subjects: 1076
Study 11985904 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 1076
Study 10681808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotensin
Number of subjects: 47
Study 10681808 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 47
Study 10681808 — intervention group
Group type: COMPARATOR
Intervention: Control (normotensive subjects)
Number of subjects: 47
Study 9197912 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 81
Study 9197912 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 81
Study 9197912 — intervention group
Group type: COMPARATOR
Intervention: 2'-chlordesmethyldiazepam
Number of subjects: 81
Study 2794190 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadup activity training program (8-hour, largely self-instructional)
Number of subjects: 26
Study 2794190 — intervention group
Group type: COMPARATOR
Intervention: Control group (randomly selected)
Number of subjects: 26
Study 1222752 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine tablets
Number of subjects: 20
Study 1222752 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine syrup
Number of subjects: 20
Study 1222752 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (both preparations)
Number of subjects: 20
Study 31175806 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed lignan supplement (50 mg secoisolariciresinol diglucoside/d)
Number of subjects: 42
Study 31175806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31175806 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed lignan supplement
Number of subjects: 42
Study 28002198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 0
Study 28002198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25381193 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline first phase insulin response (FPIR) ≤3 μU/mL during IvGTT
Number of subjects: 50
Study 25381193 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal plasma glucose ≥11.1 mmol/L measured at 30, 60 and/or 90 min during OGTT
Number of subjects: 50
Study 25381193 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of FPIR from IvGTT and maximal plasma glucose during OGTT
Number of subjects: 50
Study 25381193 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level IA-2A
Number of subjects: 50
Study 23162100 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐citrate (60 mEq daily)
Number of subjects: 201
Study 23162100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 21719806 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Single Bond (SB) Plus Adhesive with rewet dentin
Number of subjects: 40
Study 21719806 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Single Bond (SB) Plus Adhesive with dry dentin
Number of subjects: 40
Study 21719806 — intervention group
Group type: EXPERIMENTAL
Intervention: One-Step (OS) Universal Dental Adhesive System with rewet dentin
Number of subjects: 40
Study 21719806 — intervention group
Group type: EXPERIMENTAL
Intervention: One-Step (OS) Universal Dental Adhesive System with dry dentin
Number of subjects: 40
Study 21719806 — intervention group
Group type: COMPARATOR
Intervention: One-Step (OS) Universal Dental Adhesive System
Number of subjects: 40
Study 21719806 — intervention group
Group type: COMPARATOR
Intervention: Adper Single Bond (SB) Plus Adhesive
Number of subjects: 40
Study 19390093 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine case management
Number of subjects: 1665
Study 19390093 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1665
Study 16882343 — intervention group
Group type: EXPERIMENTAL
Intervention: Home UVB treatment
Number of subjects: 196
Study 16882343 — intervention group
Group type: COMPARATOR
Intervention: UVB phototherapy in a hospital outpatient clinic
Number of subjects: 196
Study 15223788 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs) with a +2.00 addition (n = 235)
Number of subjects: 469
Study 15223788 — intervention group
Group type: COMPARATOR
Intervention: Single vision lenses (SVLs; n = 234)
Number of subjects: 469
Study 15223788 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs)
Number of subjects: 469
Study 11408301 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission cardiotocography
Number of subjects: 0
Study 11408301 — intervention group
Group type: COMPARATOR
Intervention: Doppler auscultation
Number of subjects: 0
Study 9027270 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE-guided cardioversion
Number of subjects: 126
Study 9027270 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 126
Study 8237086 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position with solid bolus (piece of apple)
Number of subjects: 20
Study 8237086 — intervention group
Group type: COMPARATOR
Intervention: Sitting position with liquid bolus (5 ml water)
Number of subjects: 20
Study 8237086 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position with solid bolus (piece of apple)
Number of subjects: 20
Study 8237086 — intervention group
Group type: COMPARATOR
Intervention: Supine position with liquid bolus (5 ml water)
Number of subjects: 20
Study 3800403 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP + DM + Lorazepam (Method B)
Number of subjects: 50
Study 3800403 — intervention group
Group type: COMPARATOR
Intervention: MCP + DM (Method A)
Number of subjects: 50
Study 29736750 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone health coaching intervention
Number of subjects: 417
Study 29736750 — intervention group
Group type: COMPARATOR
Intervention: Control group (HRA only)
Number of subjects: 417
Study 27393622 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel with concurrent bevacizumab followed by AC
Number of subjects: 215
Study 27393622 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel followed by AC
Number of subjects: 215
Study 27393622 — intervention group
Group type: COMPARATOR
Intervention: AC followed by nab-paclitaxel
Number of subjects: 215
Study 27393622 — intervention group
Group type: COMPARATOR
Intervention: Overall treatment arms
Number of subjects: 215
Study 25044280 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) 200/10 μg
Number of subjects: 1675
Study 25044280 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) 400/10 μg
Number of subjects: 1675
Study 25044280 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 400 μg
Number of subjects: 1675
Study 25044280 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (F) 10 μg
Number of subjects: 1675
Study 25044280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1675
Study 25044280 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FP/S) 250/50 μg
Number of subjects: 1675
Study 25044280 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FP/S) 500/50 μg
Number of subjects: 1675
Study 23424755 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphdiaral Basistropfen (verum) - 10 drops three times daily for 105 days
Number of subjects: 248
Study 23424755 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 10 drops three times daily for 105 days
Number of subjects: 248
Study 20196908 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based newsletter intervention
Number of subjects: 49
Study 20196908 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 19462557 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 172
Study 19462557 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 172
Study 19462557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 172
Study 19462557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 172
Study 16110851 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 137
Study 16110851 — intervention group
Group type: COMPARATOR
Intervention: Propranolol + Isosorbide mononitrate (ISMN)
Number of subjects: 137
Study 16110851 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL) in noncirrhotic patients
Number of subjects: 137
Study 16110851 — intervention group
Group type: COMPARATOR
Intervention: Propranolol + Isosorbide mononitrate (ISMN) in cirrhotic patients
Number of subjects: 137
Study 16110851 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (Propranolol + ISMN)
Number of subjects: 137
Study 12769414 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-Based Medicine (EBM)
Number of subjects: 0
Study 12769414 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluations (cost-effectiveness analysis)
Number of subjects: 0
Study 10394544 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic culdoplasty with a CO2 laser
Number of subjects: 30
Study 10394544 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic culdoplasty with 5-mm laparoscopic mechanical instruments
Number of subjects: 30
Study 8520875 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally implanted catheters
Number of subjects: 74
Study 8520875 — intervention group
Group type: COMPARATOR
Intervention: IL-2 treatment alone (41 patients)
Number of subjects: 74
Study 8520875 — intervention group
Group type: COMPARATOR
Intervention: IL-2 treatment with interferon gamma (33 patients)
Number of subjects: 74
Study 2405326 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (lidocaine/prilocaine) applied 1-75 minutes before CO2 laser treatment
Number of subjects: 80
Study 2405326 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied 1-75 minutes before CO2 laser treatment
Number of subjects: 80
Study 649204 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg thrice daily for seven days
Number of subjects: 60
Study 649204 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition of the seven-day course after an interval of one week
Number of subjects: 60
Study 649204 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 2400 mg
Number of subjects: 60
Study 649204 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 2400 mg doses on successive days
Number of subjects: 60
Study 649204 — intervention group
Group type: COMPARATOR
Intervention: Single-dose groups
Number of subjects: 60
Study 649204 — intervention group
Group type: EXPERIMENTAL
Intervention: 2400 mg dosages
Number of subjects: 60
Study 31077233 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured group-based educational program (MEDIHEALTH)
Number of subjects: 0
Study 28969312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 55
Study 28969312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 26035677 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral surgical decompression of the tibial nerve and common, superficial, and deep peroneal nerves
Number of subjects: 42
Study 26035677 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral side)
Number of subjects: 42
Study 23510357 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 500
Study 23510357 — intervention group
Group type: COMPARATOR
Intervention: Men-PS
Number of subjects: 500
Study 21617090 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-coordinated care including a nephrologist
Number of subjects: 474
Study 21617090 — intervention group
Group type: COMPARATOR
Intervention: Usual care coordinated by a general practitioner
Number of subjects: 474
Study 21617090 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-coordinated care
Number of subjects: 474
Study 21617090 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 474
Study 18158695 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI per os
Number of subjects: 38
Study 18158695 — intervention group
Group type: COMPARATOR
Intervention: MRE
Number of subjects: 38
Study 17130680 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (150, 225, 300, or 375mg) administered subcutaneously every 2 or 4 weeks
Number of subjects: 100
Study 17130680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17130680 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 100
Study 12584276 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 150 mg/day for 4 weeks
Number of subjects: 31
Study 12584276 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 31
Study 10675831 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen-medrogestone combination
Number of subjects: 228
Study 9116774 — intervention group
Group type: EXPERIMENTAL
Intervention: r-FSH with LHRH agonist
Number of subjects: 62
Study 9116774 — intervention group
Group type: COMPARATOR
Intervention: r-FSH without LHRH agonist
Number of subjects: 62
Study 9116774 — intervention group
Group type: EXPERIMENTAL
Intervention: r-FSH with step-up stimulation
Number of subjects: 62
Study 9116774 — intervention group
Group type: EXPERIMENTAL
Intervention: r-FSH with step-down stimulation
Number of subjects: 62
Study 1439226 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-actuated metered dose inhaler (Aerolin in the Autohaler inhalation device)
Number of subjects: 25
Study 1439226 — intervention group
Group type: COMPARATOR
Intervention: Standard press and breathe metered dose inhaler
Number of subjects: 25
Study 3104446 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 33
Study 3104446 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 33
Study 3104446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 31843821 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted, person-centred cardiorespiratory management model
Number of subjects: 1100
Study 29302807 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted vaginal hysterectomy (LAVH) with peritoneal closure (PC)
Number of subjects: 192
Study 29302807 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted vaginal hysterectomy (LAVH) without peritoneal closure (PC)
Number of subjects: 192
Study 29302807 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy (VH) with peritoneal closure (PC)
Number of subjects: 192
Study 29302807 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy (VH) without peritoneal closure (PC)
Number of subjects: 192
Study 29302807 — intervention group
Group type: COMPARATOR
Intervention: All groups (LAVH and VH with and without PC)
Number of subjects: 192
Study 26699246 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-Color Nutrition Label
Number of subjects: 11981
Study 26699246 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Traffic Lights
Number of subjects: 11981
Study 26699246 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Tick
Number of subjects: 11981
Study 26699246 — intervention group
Group type: COMPARATOR
Intervention: Control (no front‐of‐pack exposure)
Number of subjects: 11981
Study 25046394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg or 0.5 mg)
Number of subjects: 0
Study 25046394 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 0
Study 22980341 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session aerobic exercise with low intensity (n=14)
Number of subjects: 51
Study 22980341 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session aerobic exercise with moderate intensity (n=14)
Number of subjects: 51
Study 22980341 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session aerobic exercise with high intensity (n=13)
Number of subjects: 51
Study 22980341 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 51
Study 21626816 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (50 ml)
Number of subjects: 47
Study 16999956 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH isoform distribution pattern assessment
Number of subjects: 0
Study 14641117 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) (2%)
Number of subjects: 40
Study 14641117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonanoic acid (NAA) (40%)
Number of subjects: 40
Study 14641117 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study 10896228 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (3-year low intensity exercise intervention)
Number of subjects: 140
Study 10896228 — intervention group
Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 140
Study 10896228 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 140
Study 9027792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 1.5 g i.v. preoperatively and 250 mg i.p. in the first dialysis bag (1 litre fluid)
Number of subjects: 38
Study 9027792 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 38
Study 8104044 — intervention group
Group type: EXPERIMENTAL
Intervention: Serazepine (CGS‐15040A) at doses greater than or equal to 10 mg
Number of subjects: 0
Study 8104044 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 3089950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary lithium carbonate (1.5 g)
Number of subjects: 5
Study 3089950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release lithium carbonate (1.8 g)
Number of subjects: 5
Study 30024030 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling with root planing in multiple sessions quadrant‐by‐quadrant (Q by Q)
Number of subjects: 93
Study 30024030 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling with root planing within 24 hours (one stage)
Number of subjects: 93
Study 30024030 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial HbA1c < 9%
Number of subjects: 93
Study 30024030 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial HbA1c ≥ 9%
Number of subjects: 93
Study 27461133 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri-containing lozenges (≥108 CFU L. reuteri ATCC PTA 5289 and ≥108 CFU L. reuteri DSM 17938, consumed 2× daily for approx. 7 weeks)
Number of subjects: 45
Study 27461133 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri-containing lozenges
Number of subjects: 45
Study 27461133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (devoid of L. reuteri)
Number of subjects: 45
Study 27461133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 24893377 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange-flavored water (OF)
Number of subjects: 14
Study 24893377 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemon-flavored water (LF)
Number of subjects: 14
Study 24893377 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape-flavored water (GF)
Number of subjects: 14
Study 24893377 — intervention group
Group type: COMPARATOR
Intervention: Unflavored water (W)
Number of subjects: 14
Study 23048051 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stents (R-ZES)
Number of subjects: 500
Study 23048051 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 500
Study 23048051 — intervention group
Group type: COMPARATOR
Intervention: Both R-ZES and SES
Number of subjects: 500
Study 21677121 — intervention group
Group type: EXPERIMENTAL
Intervention: Free lutein (fL) 12.2 mg
Number of subjects: 72